357 results on '"Guo, Renhua"'
Search Results
52. Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
53. Detection and Localization of Solid Tumors Utilizing the Cancer-Type-Specific Mutational Signatures
54. The clinical synergistic antitumor efficacy of Lienal Polypeptide combined with EGFR-TKIs for advanced NSCLC
55. Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC
56. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer
57. Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
58. Additional file 1 of On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial
59. The Immun-Enhancing and Synergistic Antitumor Efficacy of Lienal Polypeptide Combined with EGFR-TKIs for Advanced NSCLC
60. Efficacy and Safety of KL-A167 in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter, Single-Arm, Phase 2 Study
61. Copy number amplification-activated long non-coding RNA LINC00662 epigenetically inhibits BIK by interacting with EZH2 to regulate tumorigenesis in non-small cell lung cancer
62. Clinical significance of PIK3CA and survivin in primary adenosquamous lung carcinoma
63. Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
64. Clinicopathological significance of lymphatic vessel density marked by D2-40 and E-cadherin expression in non-small-cell lung cancer
65. Abstract CT170: D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156)
66. Additional file 1 of Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting
67. High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 With Unfavorable Prognosis
68. Reversal of Acquired Resistance to EGFR–TKI in T790M-negative Patients With Non–small-cell Lung Cancer Using Anlotinib
69. MiR‐873 inhibition enhances gefitinib resistance in non‐small cell lung cancer cells by targeting glioma‐associated oncogene homolog 1
70. RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma
71. The development and validation of a nomogram for predicting brain metastases in lung squamous cell carcinoma patients: an analysis of the Surveillance, Epidemiology, and End Results (SEER) database
72. Association of KDR Mutation With Better Clinical Outcomes in Pan-Cancer for Immune Checkpoint Inhibitors
73. A comparative genomics analysis of lung adenocarcinoma for Chinese population by using panel of recurrent mutations
74. Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration
75. Efficacy and Acquired Resistance of EGFR-TKI Combined with Chemotherapy as First-Line Treatment for Chinese Patients with Advanced Non-Small Cell Lung Cancer in a Real-world Setting
76. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFRT790M-Mutated NSCLC That Had Progressed After Prior EGFRTyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
77. Phase II Study of Weekly Irinotecan plus Cisplatin in Patients with Previously Untreated Extensive-Stage Extrapulmonary Small Cell Carcinoma
78. Metabolic disposition of [ 14 C]‐abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation
79. Checkpoint inhibitor pneumonitis in Chinese lung cancer patients: clinical characteristics and risk factors
80. High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 with Unfavorable Prognosis
81. Nomogram for Predicting Brain Metastases in Lung Squamous Cell Carcinoma Patients: A SEER -Based Study
82. Abstract CT127: A phase I study of cMET inhibitor bozitinib in patients with advanced NSCLC harboring cMET alterations
83. Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)
84. A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer
85. BRAF fusion in lung cancer.
86. A multicenter real-world study of tumor-derived DNA from pleural effusion supernatant in genomic profiling of advanced lung cancer.
87. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFRT790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial
88. Microarray expression profiling and bioinformatics analysis of circular RNA expression in lung squamous cell carcinoma
89. IL-22 Confers EGFR-TKI Resistance in NSCLC via the AKT and ERK Signaling Pathways
90. Mutations in exon 8 of TP53 are associated with shorter survival in patients with advanced lung cancer
91. Identification of Germline Mismatch Repair Gene Mutations in Lung Cancer Patients With Paired Tumor-Normal Next Generation Sequencing: A Retrospective Study
92. ALK actionable mutations (muts) within cancer types and their responses to crizotinib (CZ).
93. EGFR extracellular domain mutation in patients with lung cancer.
94. HS-10296 – A Novel Third Generation EGFR Tyrosine Kinase Inhibitor: Results of the First-in-Human Phase 1 Trial in Patients with Previously Treated EGFR Mutant Advanced Non-Small-Cell Lung Cancer
95. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
96. Metabolic disposition of [14C]‐abivertinib, an epidermal growth factor receptor tyrosine kinase inhibitor: Role of glutathione conjugation.
97. MiR‐326/Sp1/KLF3: A novel regulatory axis in lung cancer progression
98. EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small-Cell Lung Cancer
99. Cortisol, cortisone, and 4-methoxyphenylacetic acid as potential plasma biomarkers for early detection of non-small cell lung cancer
100. Next generation sequencing (NGS) based mutation profiling and heterogeneity of resistance mechanisms to AZD9291.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.